Show Summary Details
Page of

A patient presenting with painless jaundice 

A patient presenting with painless jaundice
A patient presenting with painless jaundice

Elizabeth Liniker

, Simon Johnston

, Sara Custodio-Cabello

, and Bristi Basu

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 January 2021

Pancreatic cancer is one of the most aggressive cancers with only 4% of patients are alive 5 years after diagnosis. 80-85% of patients present with advanced unresectable disease. Even completely resected pancreatic cancers have a poor prognosis with 5-year survival of 20-25% and median survival between 10-20 months. Adjuvant chemotherapy after a curative resection improves 5-year survival from <10%-20%. Role of chemoradiotherapy in locally advanced pancreatic cancer is evolving. In patients with unresectable/metastatic tumours treatment is essentially palliative including systemic treatment with gemcitabine.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.